An isogenic cell line was created to model cancer patients with the echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene and tested for its ...

Targeted therapies have significantly improved outcomes for patients with non-small cell lung cancer (NSCLC) with actionable mutations. However, many tumors inevitably develop drug resistance and ...

The drug is now approved for adjuvant treatment following tumor resection for patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) (tumors ≥ 4 cm or node ...

Dr. Dolsten’s accomplishments include the introduction of a new class of oral medications for autoimmune diseases, the development and approval of targeted anaplastic lymphoma kinase (ALK ...